Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 109,866 shares at $94.71 ($10.8M) on 2012-02-22, disclosed to the SEC on 2012-02-23.
Scheduled sale ($10.8M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $100.32 | 2,511 | $252K | 2.3% |
| 2 | $100.32 | 4,050 | $406K | 3.8% |
| 3 | $100.32 | 5,558 | $558K | 5.2% |
| 4 | $100.32 | 5,753 | $577K | 5.3% |
| 5 | $100.32 | 7,347 | $737K | 6.8% |
| 6 | $100.32 | 7,705 |
| $773K |
| 7.1% |
| 7 | $100.32 | 9,158 | $919K | 8.5% |
| 8 | $100.32 | 18,530 | $1.9M | 17.2% |
| 9 | $94.71 | 4,200 | $398K | 3.7% |
| 10 | $95.46 | 10,800 | $1.0M | 9.5% |
| 11 | $96.45 | 23,454 | $2.3M | 20.9% |
| 12 | $97.58 | 9,600 | $937K | 8.7% |
| 13 | $98.05 | 1,200 | $118K | 1.1% |
| Total | $98.54 avg | 109,866 | $10.8M | 100% |
| Filing → |
| REGN | SELL | 2014-01-03 | $5.7M | — | Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |